Research Evidence
“The fact that weight loss curves had not plateaued at 48 weeks is clinically significant — it suggests retatrutide's metabolic effects, particularly glucagon-driven energy expenditure, sustain efficacy beyond the point where most GLP-1 monotherapies begin to level off.”
The clinical evidence base for retatrutide continues to expand through multiple trials:
Phase 2 Obesity Trial (NEJM, 2023): This randomized, double-blind, placebo-controlled trial enrolled 338 adults with obesity. The 12 mg dose produced 24.2% weight loss at 48 weeks, with 100% of participants achieving ≥5% weight reduction.
Phase 2 Type 2 Diabetes Trial (Lancet, 2023): In adults with type 2 diabetes, retatrutide demonstrated clinically meaningful improvements in glycemic control alongside robust weight reductions.
Phase 3 TRIUMPH-4 Trial (December 2025, topline data): Preliminary topline results from TRIUMPH-4, conducted in 445 patients with obesity and knee osteoarthritis, reported that participants taking retatrutide 12 mg lost an average of 28.7% body weight (71.2 lbs) at 68 weeks. At the 12 mg dose, 58% of participants achieved ≥25% weight loss, 30-39% achieved ≥30%, and 23.7% achieved ≥35% weight loss. Beyond weight loss, the trial demonstrated significant improvements in joint outcomes: WOMAC pain scores improved by approximately 4.5 points from a baseline of 6 (a 76% improvement), and 12.5% of retatrutide-treated participants achieved complete zero pain compared with 4.2% on placebo. Physical function scores also improved significantly. These are preliminary results pending full peer-reviewed publication.
Phase 3 TRANSCEND-T2D-1 Trial (March 2026, topline data): In 537 adults with inadequately controlled type 2 diabetes (HbA1c 7.0-9.5%), retatrutide produced HbA1c reductions of -1.7% to -2.0% (vs -0.8% placebo) and weight loss of 11.5% to 16.8% over 40 weeks. The 12 mg dose produced average weight loss of 36.6 lbs (16.8% body weight). Notably, weight loss had not plateaued at 40 weeks, consistent with the Phase 2 obesity findings. Full results are expected to be presented at the ADA Scientific Sessions in June 2026.
Phase 2 MASLD Substudy (Nature Medicine, 2024): In a substudy of 98 participants with metabolic dysfunction-associated steatotic liver disease (MASLD), retatrutide 12 mg reduced liver fat by 82.4% compared with a 0.3% increase in the placebo group at 48 weeks. Between 82% and 93% of treated participants achieved normal liver fat levels (<5%). These results are the most dramatic liver fat reductions reported for any incretin-class therapy and have led to the SYNERGY-Outcomes Phase 3 trial (approximately 4,500 patients).
Body Composition Analysis (Lancet Diabetes & Endocrinology, 2025): In adults with type 2 diabetes, retatrutide reduced total body fat mass by up to 26.1% compared with placebo and dulaglutide. However, lean mass loss remained a concern: up to 6.5 kg of lean mass was lost, representing approximately 40% of total weight loss. Current evidence suggests that protein intake of 1.6 to 2.2 g/kg/day combined with resistance training can reduce lean mass loss to 15-20% of total weight lost.
Anti-Cancer Preclinical Data (npj Metabolic Health and Disease, 2025): In preclinical models, retatrutide reduced pancreatic tumor volume by 14-fold compared with controls (semaglutide achieved only a 4-fold reduction) and lung adenocarcinoma volume by 17-fold. Anti-tumor effects persisted even after drug withdrawal and subsequent weight regain. The mechanism involves enhanced CD8+ T cell infiltration and reduced immunosuppressive cells. These are early-stage findings in animal models and cannot be extrapolated to human cancer treatment, but they suggest that triple-receptor agonism may have anti-proliferative properties beyond what single GLP-1 agonists provide.
Meta-Analysis (2024): A systematic review confirmed retatrutide demonstrated significant improvements in body weight and metabolic outcomes with an appropriate safety profile.